How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

23,849 results for

Malaria

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

1. RTS,S/AS01E malaria vaccine (Mosquirix). Children living in malaria-endemic regions: little efficacy, poorly documented harms

RTS,S/AS01E malaria vaccine (Mosquirix). Children living in malaria-endemic regions: little efficacy, poorly documented harms Prescrire IN ENGLISH - Spotlight ''RTS,S/AS01E malaria vaccine (Mosquirix°). Children living in malaria-endemic regions: little efficacy, poorly documented harms'', 1 January 2017 {1} {1} {1} | | > > > RTS,S/AS01E malaria vaccine (Mosquirix°). Children living in malaria-endemic regions: little efficacy, poorly documented harms Spotlight Every month, the subjects (...) in Prescrire’s Spotlight. 100 most recent :  |   |   |   |   |   |   |   |   |  Spotlight RTS,S/AS01E malaria vaccine (Mosquirix°). Children living in malaria-endemic regions: little efficacy, poorly documented harms FEATURED REVIEW In late 2016, the harm-benefit balance of the RTS,S/AS01E malaria vaccine is highly uncertain, but its evaluation must continue where the vaccine is much needed. Full review (4 pages) available for download

2017 Prescrire

2. Regional malaria action plan 2016–2020: towards a malaria-free Region

Regional malaria action plan 2016–2020: towards a malaria-free Region Regional malaria action plan 2016–2020: towards a malaria-free Region JavaScript is disabled for your browser. Some features of this site may not work without it. Toggle navigation Toggle navigation Search Browse Statistics Related Links Regional malaria action plan 2016–2020: towards a malaria-free Region View/ Open Rights View Statistics Altmetrics Share Citation World Health Organization, Regional Office for the Eastern (...) Mediterranean . (‎2017)‎. Regional malaria action plan 2016–2020: towards a malaria-free Region. World Health Organization. Regional Office for the Eastern Mediterranean. . License: CC BY-NC-SA 3.0 IGO Description 44 p. Gov't Doc # WHO-EM/MAL/385/E Collections Language English Metadata Related items Showing items related by title and MeSH subject.  Executive Board, 83 (‎ EB83/19 , 1988 )‎  Executive Board, 85 (‎ EB85/10 , 1989 )‎  Executive Board, 73 (‎ EB73/9 , 1983 )‎ View Item

2017 WHO

3. World malaria day 2017: malaria prevention works, let's close the gap

World malaria day 2017: malaria prevention works, let's close the gap let’s close the gap For further information, please contact: Global Malaria Programme World Health Organization 20 Avenue Appia CH-1211 Geneva 27 Switzerland www.who.int/malaria Malaria prevention works World Malaria d ay 2017© World Health Organization 2017. Some rights reserved. This work is available under the CC BY-NC-SA 3.0 IGO licence. WHO/HTM/GMP/2017.6 Printed in FranceFOREWORD As World Malaria Day 2017 approaches (...) , there is much to celebrate. According to the latest estimates from WHO, many countries with ongoing malaria transmission have reduced their disease burden significantly. On a global scale, the rate of new malaria cases fell by 21% between 2010 and 2015. Malaria death rates fell by 29% in the same 5-year period (figure 1). In sub-Saharan Africa, where malaria is heavily concentrated, access to key interventions is expanding rapidly, particularly for the groups most vulnerable to infection and death. Since

2017 WHO

4. Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. (PubMed)

Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria. The World Health Organization (WHO) recommends artemisinin-based combination therapies (ACTs) to treat uncomplicated Plasmodium falciparum (P falciparum) malaria. Concerns about artemisinin resistance have led to global initiatives to develop new partner drugs to protect artemisinin derivatives in ACT. Pyronaridine-artesunate is a novel ACT.To evaluate the efficacy of pyronaridine-artesunate compared (...) to alternative ACTs for treating people with uncomplicated P falciparum malaria, and to evaluate the safety of pyronaridine-artesunate and other pyronaridine treatments compared to alternative treatments.We searched the Cochrane Infectious Diseases Group Specialized Register; Cochrane Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE; Embase; and LILACS. We also searched ClinicalTrials.gov, the WHO International Clinical Trials Registry Platform Search Portal

2019 Cochrane

5. Malaria infection

Malaria infection Malaria infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Malaria infection Last reviewed: February 2019 Last updated: February 2019 Summary In Western countries, almost all malaria occurs in travellers; therefore, the diagnosis may be missed if a history of travel is not elicited. Patients typically present with non-specific symptoms such as fever, chills, sweats, headache, and myalgia (...) . Examination of a Giemsa-stained blood film remains the diagnostic test of choice. Once the diagnosis of malaria is confirmed, treatment should be started urgently, as a delay may be associated with disease progression and complications. Management should be undertaken in conjunction with an infectious diseases specialist. Definition Malaria is a parasitic infection caused by protozoa of the genus Plasmodium . Five species are known to infect humans; Plasmodium falciparum is the most life-threatening. Snow

2019 BMJ Best Practice

6. Artemether for severe malaria. (PubMed)

Artemether for severe malaria. In 2011 the World Health Organization (WHO) recommended parenteral artesunate in preference to quinine as first-line treatment for people with severe malaria. Prior to this recommendation many countries, particularly in Africa, had begun to use artemether, an alternative artemisinin derivative. This Cochrane Review evaluates intramuscular artemether compared with both quinine and artesunate.To assess the efficacy and safety of intramuscular artemether versus any (...) other parenteral medication in the treatment of severe malaria in adults and children.We searched the Cochrane Infectious Diseases Group Specialized Register, CENTRAL (the Cochrane Library), MEDLINE, Embase, and LILACS, ISI Web of Science, conference proceedings, and reference lists of articles. We also searched the WHO International Clinical Trial Registry Platform, ClinicalTrials.gov, and the metaRegister of Controlled Trials (mRCT) for ongoing trials up to 7 September 2018. We checked

Full Text available with Trip Pro

2019 Cochrane

7. Indoor residual spraying for preventing malaria in communities using insecticide-treated nets. (PubMed)

Indoor residual spraying for preventing malaria in communities using insecticide-treated nets. Insecticide-treated nets (ITNs) and indoor residual spraying (IRS) are used to control malaria vectors. Both strategies use insecticides to kill mosquitoes that bite and rest indoors. For ITNs, the World Health Organization (WHO) only recommended pyrethroids until 2018, but mosquito vectors are becoming resistant to this insecticide. For IRS, a range of insecticides are recommended. Adding IRS to ITNs (...) may improve control, simply because two interventions may be better than one; it may improve malaria control where ITNs are failing due to pyrethroid resistance; and it may slow the emergence and spread of pyrethroid resistance.To summarize the effect on malaria of additionally implementing IRS, using non-pyrethroid-like or pyrethroid-like insecticides, in communities currently using ITNs.We searched the Cochrane Infectious Diseases Group Specialized Register; the Cochrane Central Register

Full Text available with Trip Pro

2019 Cochrane

8. Mass media exposure and its impact on malaria prevention behaviour among adult women in sub-Saharan Africa: results from malaria indicator surveys (PubMed)

Mass media exposure and its impact on malaria prevention behaviour among adult women in sub-Saharan Africa: results from malaria indicator surveys Mass media exposure plays a pivotal role in health communication and adoption of a healthy lifestyle. In this study, we aimed to measure the prevalence of malaria prevention behaviour among adult women in eight malaria-endemic countries in sub-Saharan Africa (SSA), and assess the influence of mass media exposure in the adoption of those (...) behaviours.For this study, we collected cross-sectional data on 46,822 women aged between 15 and 49 years from the Malaria Indicator Surveys (MIS) conducted in Burkina Faso, Ghana, Mali, Malawi, Kenya, Nigeria, Sierra Leone and Uganda. As the outcome variable, malaria prevention behaviour was proxied by the use of insecticide treated nets (ITNs) and uptake of antimalarial drugs in last pregnancy.The overall prevalence of sleeping under ITN and that of taking antimalarial drug during the last pregnancy

Full Text available with Trip Pro

2018 Global health research and policy

9. Mosquito repellents for malaria prevention. (PubMed)

Mosquito repellents for malaria prevention. Malaria is an important cause of illness and death across endemic regions. Considerable success against malaria has been achieved within the past decade mainly through long-lasting insecticide-treated nets (LLINs). However, elimination of the disease is proving difficult as current control methods do not protect against mosquitoes biting outdoors and when people are active. Repellents may provide a personal protection solution during these times.To (...) assess the impact of topical repellents, insecticide-treated clothing, and spatial repellents on malaria transmission.We searched the following databases up to 26 June 2017: the Cochrane Infectious Diseases Group Specialized Register; the Central Register of Controlled Trials (CENTRAL), published in the Cochrane Library; MEDLINE; Embase; US AFPMB; CAB Abstracts; and LILACS. We also searched trial registration platforms and conference proceedings; and contacted organizations and companies for ongoing

Full Text available with Trip Pro

2018 Cochrane

14. Mefloquine for preventing malaria in pregnant women. (PubMed)

Mefloquine for preventing malaria in pregnant women. The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa. However, parasite resistance to sulfadoxine-pyrimethamine has been increasing steadily in some areas of the region. Moreover, HIV-infected women on cotrimoxazole prophylaxis cannot receive sulfadoxine-pyrimethamine because (...) of potential drug interactions. Thus, there is an urgent need to identify alternative drugs for prevention of malaria in pregnancy. One such candidate is mefloquine.To assess the effects of mefloquine for preventing malaria in pregnant women, specifically, to evaluate:• the efficacy, safety, and tolerability of mefloquine for preventing malaria in pregnant women; and• the impact of HIV status, gravidity, and use of insecticide-treated nets on the effects of mefloquine.We searched the Cochrane Infectious

Full Text available with Trip Pro

2018 Cochrane

15. Mefloquine for preventing malaria in pregnant women. (PubMed)

Mefloquine for preventing malaria in pregnant women. The World Health Organization recommends intermittent preventive treatment in pregnancy (IPTp) with sulfadoxine-pyrimethamine for malaria for all women who live in moderate to high malaria transmission areas in Africa. However, parasite resistance to sulfadoxine-pyrimethamine has been increasing steadily in some areas of the region. Moreover, HIV-infected women on cotrimoxazole prophylaxis cannot receive sulfadoxine-pyrimethamine because (...) of potential drug interactions. Thus, there is an urgent need to identify alternative drugs for prevention of malaria in pregnancy. One such candidate is mefloquine.To assess the effects of mefloquine for preventing malaria in pregnant women, specifically, to evaluate:• the efficacy, safety, and tolerability of mefloquine for preventing malaria in pregnant women; and• the impact of HIV status, gravidity, and use of insecticide-treated nets on the effects of mefloquine.We searched the Cochrane Infectious

Full Text available with Trip Pro

2018 Cochrane

16. Insecticide-treated nets for preventing malaria. (PubMed)

Insecticide-treated nets for preventing malaria. A previous version of this Cochrane Review identified that insecticide-treated nets (ITNs) are effective at reducing child mortality, parasite prevalence, and uncomplicated and severe malaria episodes. Insecticide-treated nets have since become a core intervention for malaria control and have contributed greatly to the dramatic decline in disease incidence and malaria-related deaths seen since the turn of the millennium. However, this time period (...) has also seen a rise in resistance to pyrethroids (the insecticide used in ITNs), raising questions over whether the evidence from trials conducted before resistance became widespread can be applied to estimate the impact of ITNs on malaria transmission today.The primary objective of this review was to assess the impact of ITNs on mortality and malaria morbidity, incorporating any evidence published since the previous update into new and existing analyses, and assessing the certainty

Full Text available with Trip Pro

2018 Cochrane

17. Insecticide space spraying for preventing malaria transmission. (PubMed)

Insecticide space spraying for preventing malaria transmission. Space spraying is the dispersal of a liquid fog of insecticide into an outdoor area to kill adult insects. It has been regularly used in public health and pest control programmes, including use as an emergency response to malaria epidemics. This Cochrane Review aims to assist the decision-making of malaria vector control programmes by summarizing the evidence of the impact of space spraying on malaria transmission.The review's (...) primary objective was to evaluate the impact of space spraying on malaria transmission, or the incremental impact when applied in combination with other malaria control methods, in comparison to equivalent conditions with no space spraying intervention.To guide future evaluations of space spraying, a secondary objective was to identify and summarize the range of space spraying strategies that have been trialled, those which were promising and warrant further evaluation, and those which appear unlikely

Full Text available with Trip Pro

2018 Cochrane

18. Malaria infection

Malaria infection Malaria infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Malaria infection Last reviewed: February 2019 Last updated: February 2019 Summary In Western countries, almost all malaria occurs in travellers; therefore, the diagnosis may be missed if a history of travel is not elicited. Patients typically present with non-specific symptoms such as fever, chills, sweats, headache, and myalgia (...) . Examination of a Giemsa-stained blood film remains the diagnostic test of choice. Once the diagnosis of malaria is confirmed, treatment should be started urgently, as a delay may be associated with disease progression and complications. Management should be undertaken in conjunction with an infectious diseases specialist. Definition Malaria is a parasitic infection caused by protozoa of the genus Plasmodium . Five species are known to infect humans; Plasmodium falciparum is the most life-threatening. Snow

2018 BMJ Best Practice

19. Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. (PubMed)

Piperonyl butoxide (PBO) combined with pyrethroids in insecticide-treated nets to prevent malaria in Africa. Public health strategies that target mosquito vectors, particularly pyrethroid long-lasting insecticidal nets (LLINs), have been largely responsible for the substantial reduction in the number of people in Africa developing malaria. The spread of insecticide resistance in Anopheles mosquitoes threatens these impacts. One way to control insecticide-resistant populations is by using (...) to LLINs improves their efficacy.1. Evaluate whether adding PBO to pyrethroid LLINs increases the epidemiological and entomological effectiveness of the nets.2. Compare the effects of pyrethroid-PBO nets currently in commercial development or on the market with their non-PBO equivalent in relation to:a. malaria infection (prevalence or incidence);b. entomological outcomes.We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register; CENTRAL, MEDLINE, Embase, Web of Science, CAB

Full Text available with Trip Pro

2018 Cochrane

20. Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial (PubMed)

Dihydroartemisinin-piperaquine for intermittent preventive treatment of malaria during pregnancy and risk of malaria in early childhood: A randomized controlled trial Intermittent preventive treatment of malaria in pregnancy (IPTp) with dihydroartemisinin-piperaquine (IPTp-DP) has been shown to reduce the burden of malaria during pregnancy compared to sulfadoxine-pyrimethamine (IPTp-SP). However, limited data exist on how IPTp regimens impact malaria risk during infancy. We conducted a double (...) -blinded randomized controlled trial (RCT) to test the hypothesis that children born to mothers given IPTp-DP would have a lower incidence of malaria during infancy compared to children born to mothers who received IPTp-SP.We compared malaria metrics among children in Tororo, Uganda, born to women randomized to IPTp-SP given every 8 weeks (SP8w, n = 100), IPTp-DP every 8 weeks (DP8w, n = 44), or IPTp-DP every 4 weeks (DP4w, n = 47). After birth, children were given chemoprevention with DP every 12

Full Text available with Trip Pro

2018 EvidenceUpdates

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>